Home

Собствен вкъщи Разположени nmd pharma aarhus Представляват доволен Правилно

Labiotech.eu on Twitter:
Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle Neuromuscular Transmission Disorders #BioEquity2016… "

Tunge pengetanke klar til nye investeringer i biotekselskab fra Aarhus
Tunge pengetanke klar til nye investeringer i biotekselskab fra Aarhus

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders

Management — NMD Pharma
Management — NMD Pharma

Company Presentation
Company Presentation

NMD bags €38M to run orphan neuromuscular disease trials | FierceBiotech
NMD bags €38M to run orphan neuromuscular disease trials | FierceBiotech

NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders

Nmd Pharma A/S, Aarhus N | firma | krak.dk
Nmd Pharma A/S, Aarhus N | firma | krak.dk

Investors — NMD Pharma
Investors — NMD Pharma

NMD Pharma - Inkef capital
NMD Pharma - Inkef capital

Event: Aarhus - Brew Your Own: Meet the founders - Biopeople
Event: Aarhus - Brew Your Own: Meet the founders - Biopeople

NMD Pharma
NMD Pharma

NMD Pharma
NMD Pharma

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for  the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma — NMD Pharma
NMD Pharma — NMD Pharma

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

NMD Pharma to advance neuromuscular disorder therapies with €38m Series A  round
NMD Pharma to advance neuromuscular disorder therapies with €38m Series A round

Company Presentation
Company Presentation

Management — NMD Pharma
Management — NMD Pharma

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for  the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co

Management — NMD Pharma
Management — NMD Pharma

Contact — NMD Pharma
Contact — NMD Pharma

Company Presentation
Company Presentation

NMD Pharma
NMD Pharma